BRIM team chart

A Team Approach to Translational Science

Success doesn’t just come from a winning idea or an exciting new concept.  Success comes from having a dedicated team behind that idea, with the enthusiasm and commitment to drive it from concept to clinic. The people behind the peptide…

Read More

BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome

Taipei, Taiwan, May 17th, 2022: BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage…

Read More

A Peptide Approach to Regenerative Medicine

Are regenerative peptides the answer to current challenges in the development of treatments for unmet needs? In an article published in PharmaTimes Magazine, Frank Lee, CSO, and Maria Chen, VP of Business Development, discuss the potential of pigment epithelium-derived factor…

Read More

Overcoming Challenges to Provide Affordable Treatments

Peptides and proteins have a wide range of therapeutic uses. These options come, however, with their own advantages and limitations, which must be identified before selecting the right treatment. In an article published in European Biopharmaceutical Review, Maria Chen, VP…

Read More

Download BRIM's Corporate Overview